At the news
? BULLISHIMPACT 7/10 PRESS-RELEASE filed Jul 27, 2026 at 07:00 ET
Neumora Therapeutics announced favorable pre-clinical toxicology results for NMRA-215, a brain-penetrant oral NLRP3 inhibitor for obesity and cardiometabolic disease. A repeat 13-week rat study showed no unexpected adverse findings, resolving concerns from a prior study where 5 of 142 animals had issues. The company plans to submit an IND in Q4 2026 and initiate a clinical study in 2026.
- Repeat 13-week rat toxicology study (n=162) showed no unexpected in-life adverse findings, resolving prior concerns from a study where 5 of 142 animals had issues.
- Company plans to submit an IND for NMRA-215 in Q4 2026 and initiate a clinical study in 2026.
- NMRA-215 demonstrated class-leading weight loss as monotherapy in a diet-induced obesity mouse model, additive weight loss with semaglutide, and improved peripheral cardiometabolic biomarkers.
- NMRA-215 is a potentially best-in-class, highly brain-penetrant, oral NLRP3 inhibitor targeting obesity and cardiometabolic disorders.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access